Table 2.
Potential key candidate genes identified from the transcriptome.
| Gene name | log2FC of HBF/LBF | FDR of HBF/LBF | log2FC in HIMF/LIMF | FDR in HIMF/LIMF | Gene function |
|---|---|---|---|---|---|
| FASN | − 2.96 | 1.00E−06 | 0.48 | 0.676 | Metabolic pathways, fatty acid metabolism, AMPK signaling pathway, insulin signaling pathway, fatty acid biosynthesis |
| CA3 | − 2.26 | 4.72E−03 | − 0.85 | 0.579 | Metabolic pathways, nitrogen metabolism, cellular anatomical entity, cellular process, metabolic process, binding, intracellular |
| TKT | − 1.06 | 5.20E−04 | 0.21 | 0.978 | Metabolic pathways, carbon metabolism, amino acid biosynthesis, pentose phosphate pathway, alpha-amino acid metabolic process, sulfur compound metabolic process, |
| KLF2 | 1.41 | 5.50E−05 | 0.16 | 0.991 | White fat cell differentiation |
| ACAT1 | − 1.02 | 7.10E−05 | − 0.43 | 0.953 | Reproductive structure development, sulfur amino acid biosynthetic process, metabolic pathways, valine, leucine, and isoleucine degradation, propanoate metabolism, carbon metabolism, pyruvate metabolism |
| ALDH1L1 | − 2.36 | 8.61E−08 | − 0.91 | 0.913 | One carbon pool by folate, One Carbon Metabolism, Folate Metabolism |
| ECHDC1 | − 1.43 | 5.01E−09 | − 0.02 | 0.996 | Metabolic pathways, propanoate metabolism, metabolic process, catalytic activity |
| ADHFE1 | − 1.85 | 2.19E−08 | − 0.51 | 0.928 | Reproduction, alpha-amino acid metabolic process, sulfur compound metabolic process, reproductive structure development, regulation of muscle system process, citric acid cycle, respiratory electron transport, pyruvate metabolism |
| ACADSB | − 1.19 | 4.80E−05 | − 0.29 | 0.960 | Metabolic pathways, valine, leucine, and isoleucine degradation, fatty acid degradation, fatty acid metabolism |
| ALDH6A1 | − 1.18 | 4.35E−03 | − 0.79 | 0.542 | Metabolic pathways, valine, leucine, and isoleucine degradation, propanoate metabolism, carbon metabolism, inositol phosphate metabolism, beta-alanine metabolism |
| AACS | − 2.28 | 2.28E−10 | − 0.68 | 0.733 | Metabolic pathways, valine, leucine, and isoleucine degradation, butanoate metabolism |
| SERPINE1 | 1.64 | 3.08E−03 | − 0.99 | 0.772 | Adipogenesis, blood clotting cascade, complement and coagulation cascades |
| PPARD | 1.31 | 5.48E−04 | − 1.19 | 0.238 | Pathways in cancer, PPAR signaling pathway, acute myeloid leukemia, Wnt signaling pathway, ion binding, metal ion binding, small molecule metabolic process |
| UBD | 1.02 | 1.18E−03 | 0.07 | 0.995 | Proteasome binding, protein ubiquitination, positive regulation of apoptotic process |
| UCP2 | 1.45 | 2.75E−03 | 0.28 | 0.974 | Anatomical structure morphogenesis, reproductive structure development, cardiac muscle tissue development, cell junction organization, muscle cell development |
| FBP1 | − 1.78 | 4.80E−03 | − 3.34 | – | Negative regulation of glycolytic process, regulation of gluconeogenesis, fructose 6-phosphate metabolic process, negative regulation of cell growth |
| ACSS3 | − 1.20 | 9.09E−03 | − 0.74 | 0.628 | Metabolic pathways, propanoate metabolism |
| PFKFB1 | − 3.27 | 6.02E−06 | 0.90 | 0.269 | Regulation of glycolysis by fructose 2,6-bisphosphate metabolism, metabolism, glycolysis, glucose metabolism, focal adhesion-PI3K-Akt-mTOR-signaling pathway, carbohydrate metabolism |
| GCDH | − 1.17 | 2.19E−08 | − 0.20 | 0.989 | Metabolic pathways, fatty acid degradation, lysine degradation, tryptophan metabolism |
| ACP5 | 2.07 | 7.52E−03 | 0.92 | 0.953 | Metabolism, metabolism of water-soluble vitamins and cofactors, NAD phosphorylation and dephosphorylation |
| PRG4 | 3.62 | 5.26E−01 | − 1.39 | 1.948 | Phospholipase-C Pathway, ERK signaling, integrin pathway, MAPK signaling |
| LPL | 1.00 | 2.14E−03 | 1.16 | 0.102 | Fatty acid β-oxidation, adipogenesis, PPAR signaling pathway, lipoprotein metabolism, triacylglyceride synthesis |
| PRKAG3 | − 2.73 | 7.80E−03 | 1.88 | 0.001 | Longevity regulating pathway, AMPK signaling pathway, apelin signaling pathway, insulin signaling pathway, oxytocin signaling pathway, non-alcoholic fatty liver disease, tight junction |
| RETREG1 | − 0.74 | 4.03E−01 | − 2.72 | – | nucleolus, endoplasmic reticulum, Golgi apparatus |
| PRKAG2 | − 0.50 | 6.82E−02 | − 2.57 | 0.004 | Vitamin digestion and absorption, thermogenesis, lipid metabolism |
| SMPDL3A | 0.21 | 8.69E−01 | − 3.53 | – | Vitamin digestion and absorption, sphingomyelin phosphodiesterase activity, sphingomyelin metabolic process, cellular lipid metabolic process, membrane lipid catabolic process, sphingolipid catabolic process, phospholipid catabolic process |
| IRS2 | − 0.04 | 9.72E−01 | − 1.79 | 3.0E−04 | Adipogenesis genes, focal adhesion-PI3K-Akt-mTOR-signaling pathway, erythropoietin activates phosphoinositide-3-kinase, IL-13 signaling pathway, signaling by type 1 insulin-like growth factor 1 receptor |
| BDH1 | − 0.06 | 9.75E−01 | − 1.93 | 0.009 | Vitamin digestion and absorption, butanoate metabolism, metabolic pathways, ketone body catabolism, lipid metabolism |
| PPARA | − 0.58 | 5.02E−01 | − 1.59 | 0.001 | Vitamin digestion and absorption, cAMP signaling pathway, Hepatitis C |
| GK | 0.07 | 9.67E−01 | − 1.99 | 0.004 | Vitamin digestion and absorption, glycerolipid metabolism, metabolic pathways |
| LEP | 0.72 | 3.29E−01 | 3.17 | 2.3E−04 | AMP-activated protein kinase Signaling, adipocytokine signaling pathway, peptide hormone metabolism, cytokine-cytokine receptor interaction |
LBF low backfat thickness, HBF high backfat thickness, HIMF high intramuscular fat, LIMF low intramuscular fat, log2FC log2 fold change, FDR false discovery rate.